Trial Profile
Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 09 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Nov 2014 New trial record